Celerion
Lincoln, Nebraska, 68502, United States
NCT Number: NCT07158437
This first-in-human study is a randomized, double-blind, placebo-controlled, single-ascending dose and multiple-ascending dose study of SL-325 in healthy volunteers.
This study is active but is not currently recruiting participants.
18 year–55 year
All sexes
Interventional
Phase 1
Lincoln, Nebraska, 68502, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
DR3 blocking antibody
Normal saline
Time frame: Day 1 through 75 days after last dose
Incidence and severity of treatment-emergent adverse events
Time frame: Day 1 through 75 days after last dose
Maximum observed concentration
Time frame: Day 1 through 75 days after last dose
Time at which the maximum concentration is observed
Time frame: Day 1 through 75 days after last dose
Minimum observed concentration following a single dose
Time frame: Day 1 through 75 days after last dose
Area under the concentration-time curve
Time frame: Day 1 through 75 days after last dose
Terminal elimination half-life
Time frame: Day 1 through 75 days after last dose
Clearance
Time frame: Day 1 through 75 days after last dose
Volume of distribution
Time frame: Day 1 through 75 days after last dose
Time frame: Day 1 through 75 days after last dose
Time frame: Day 1 through 75 days after last dose
Time frame: Day 1 through 75 days after last dose
Time frame: Day 1 through 75 days after last dose
Time frame: Day 1 through 75 days after last dose
Shattuck Labs, Inc.
Industry
A Randomized, Double-Blind, Placebo-Controlled Single-Ascending Dose and Multiple-Ascending Dose Phase 1 Study of SL-325 in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07736599
Behavior, Behavioral Symptoms
Amasya, Turkey (Türkiye)
View Trial DetailsNCT00410241
Arterial Occlusive Diseases, Arteriosclerosis
Bethesda, Maryland, United States
View Trial DetailsNCT07646548
Healthy Volunteers
Hialeah, Florida, United States
View Trial DetailsNCT07567781
Healthy Volunteers
Grayslake, Illinois, United States
View Trial Details